<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="189603">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00625079</url>
  </required_header>
  <id_info>
    <org_study_id>IPF/PH</org_study_id>
    <nct_id>NCT00625079</nct_id>
  </id_info>
  <brief_title>Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil</brief_title>
  <official_title>Randomized Placebo-Controlled Study of Sildenafil For The Treatment of Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pulmonary Arterial Hypertension (PAH) in the setting of Idiopathic Pulmonary Fibrosis(IPF)is
      a risk factor for morbidity and mortality in the peri-lung transplant(LT) setting. Currently
      there is no significant data to support the use of pulmonary vasodilators for PAH in the
      setting of interstitial lung disease such as IPF. The majority of IPF patients have PAH
      either at rest or during exercise. The study hypothesis is that sildenafil may improve
      morbidity and mortality in the peri-LT setting in both IPF cohorts with either resting or
      exercise PAH.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2007</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <primary_completion_date type="Anticipated">June 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>6 minute walk distance</measure>
    <time_frame>monthly until date of lung transplantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Right heart catheterization hemodynamics</measure>
    <time_frame>initial right heart catheterization compared to catheterization done on day of lung transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>chemokine analysis on peripheral blood</measure>
    <time_frame>monthly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life assessment</measure>
    <time_frame>monthly</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <condition>Interstitial Lung Disease</condition>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>There are two placebo comparators.... one for the group of patients with resting PAH and another for the group of patients with exercise PAH</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>There are two active comparators, one group with resting PAH and another with exercise PAH, both receiving drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>this group of patients has no evidence for either resting or exercise PAH but will be followed without specific drug intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sildenafil</intervention_name>
    <description>sildenafil 20mg three times per day (orally)</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Revatio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sildenafil</intervention_name>
    <description>sildenafil (placebo) 20mg three times per day (orally)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with Idiopathic Pulmonary Fibrosis referred for lung transplantation at our
             medical center

          -  Minimal 6 minute walk distance of 50 meters; must be able to conduct supine exercise
             during heart catheterization

        Exclusion Criteria:

          -  Non ambulatory

          -  Prior adverse reaction/allergy to sildenafil or other PDE-5 Inhibitors

          -  Any other pulmonary vasodilator within one month of enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rajan Saggar, MD</last_name>
    <role>Study Director</role>
    <affiliation>David Geffen School of Medicine, UCLA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rajan Saggar, MD</last_name>
    <phone>310-825-5635</phone>
    <email>rsaggar@mednet.ucla.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michaela Dyke</last_name>
    <phone>310-825-5635</phone>
    <email>mdyke@mednet.ucla.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>David Geffen School of Medicine UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1690</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michaela Dyke</last_name>
      <phone>310-825-5635</phone>
      <email>mdyke@mednet.ucla.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2008</verification_date>
  <lastchanged_date>February 19, 2008</lastchanged_date>
  <firstreceived_date>February 19, 2008</firstreceived_date>
  <responsible_party>
    <name_title>Rajan Saggar</name_title>
    <organization>David Geffen School of Medicine UCLA</organization>
  </responsible_party>
  <keyword>pulmonary hypertension</keyword>
  <keyword>pulmonary arterial hypertension</keyword>
  <keyword>interstitial lung disease</keyword>
  <keyword>idiopathic pulmonary fibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
